These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
    Author: Metz R, Delgado M, Keiling R, Cappelaere P, Armand JP, Prevot G, Misset JL, Grimbert J, Mathe G.
    Journal: Invest New Drugs; 1985; 3(2):163-6. PubMed ID: 4019119.
    Abstract:
    In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose. After the EORTC Clinical Screening Group phase II trial we have conducted an "expected difference method" comparative phase II trial using the combination DOX, VCR, CPM, FU and the combination of MTX (10mg/m2), VCR, CPM and FU on a population of 50 breast carcinoma patients similar to those taking part in the first study. The reasons for similarity of action will be presented and discussed.
    [Abstract] [Full Text] [Related] [New Search]